[Treatment of pulmonary arterial hypertension in children]

Area of Science:

• Pediatric Cardiology
• Pulmonology
• Pharmacology

Background:

• Pediatric pulmonary hypertension (PH) management has evolved significantly.
• Traditional therapies offer limited mortality reduction and are for select patients.
• Emerging pulmonary vasodilators from adult trials offer new therapeutic avenues.

Purpose of the Study:

• To review current and emerging treatment strategies for pediatric pulmonary hypertension.
• To evaluate the efficacy and limitations of new pharmacologic agents.
• To highlight the need for further research in pediatric PH therapies.

Main Methods:

• Review of recent clinical trials and therapeutic guidelines for pediatric PH.
• Analysis of data on epoprostenol, bosentan, and sildenafil in pediatric populations.
• Discussion of invasive strategies and future research directions.

Main Results:

• Epoprostenol (prostacyclin) demonstrates reduced mortality and improved symptoms in pediatric patients.
• Bosentan, an oral endothelin receptor blocker, improves functional status in children with NYHA class II and III PH.
• Sildenafil (type V phosphodiesterase inhibitor) shows future therapeutic potential, pending evaluation.
• Catheter-based atrial septostomy may be beneficial in specific pediatric PH cases.

Conclusions:

• Newer agents like epoprostenol and bosentan offer improved outcomes for pediatric pulmonary hypertension.
• Oral bosentan is suitable for moderate symptom severity (NYHA class II-III).
• Randomized controlled trials are crucial to establish safety and efficacy of novel pediatric PH therapies.